The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
PRIMO 2023 | Choosing the best ALK inhibitor for lung cancer
Jorge Nieva, MD, University of California, San Francisco, CA, gives a summary of current ALK inhibitors for lung cancer. There are multiple ALK inhibitors available such as brigatinib and alectinib, which are both second generation inhibitors. Lorlatinib is a third generation inhibitor, which has shown to be effective in resistant mutants, albeit with a higher toxicity profile. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
